Abstract: The present invention refers to a dural sealing system (100) comprising an implant (10), joined to a guiding thread (20); a transfer device (30), provided with a grip portion (30a) and a hollow portion (30b), said hollow portion (30b) terminating, at a first end, in a nozzle (30c) that can be coupled to an epidural needle (200), said hollow portion (30b) also terminating in a second end fitted with an entry region (30d); and an introductory device (70) comprising a tube (70a) with a hollow interior section, provided with a first free end and a second closed end, attached to a stop (70b).

Abstract: The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

Abstract: The invention relates to a neovaginal prosthesis formed by an essentially cylindrical hollow main body comprising a closed upper end and an open lower end, and a securing plate intended to connect to the lower end of the main body.

Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.